The Hsp60 peptide p277 enhances anti-CD3 mediated diabetes remission in non-obese diabetic mice

Journal of Autoimmunity
Ghanashyam SarikondaMatthias von Herrath

Abstract

Type 1 diabetes (T1D) is characterized by the immune-mediated destruction of pancreatic beta cells leading to inadequate glycemic control. Trials with immunomodulatory monotherapies have shown that the disease course can in principle be altered. The observed preservation of endogenous insulin secretion however is typically transient and chronic treatment is often associated with significant side effects. Here we combined anti-CD3 with the Hsp60 peptide p277, two drugs that have been evaluated in Phase 3 trials, to test for enhanced efficacy. Female NOD mice with recent onset diabetes were given 5 μg anti-CD3 i.v., on three consecutive days in combination with 100 μg of p277 peptide in IFA s.c., once weekly for four weeks. Anti-CD3 alone restored normoglycemia in 44% of the mice while combination therapy with anti-CD3 and p277 induced stable remission in 83% of mice. The observed increase in protection occurred only in part through TLR2 signaling and was characterized by increased Treg numbers and decreased insulitis. These results have important implications for the design of combination therapies for the treatment of T1D.

References

Apr 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·D EliasI R Cohen
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·D EliasI R Cohen
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Mar 4, 2000·Proceedings of the National Academy of Sciences of the United States of America·L YuG S Eisenbarth
May 31, 2002·The New England Journal of Medicine·Kevan C HeroldJeffrey A Bluestone
Oct 4, 2002·The New England Journal of Medicine·Joep Killestein
Apr 22, 2006·The Journal of Clinical Investigation·Damien BressonMatthias von Herrath
Jun 13, 2006·The Journal of Clinical Investigation·Alexandra Zanin-ZhorovIrun R Cohen
Jul 21, 2007·Nature Reviews. Immunology·Lucienne Chatenoud, Jeffrey A Bluestone
Aug 20, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Damien BressonMatthias von Herrath
Jul 16, 2010·Clinical and Experimental Immunology·J B MatthewsUNKNOWN ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group
Jul 20, 2010·Immunotherapy·Matthias von Herrath
Nov 4, 2010·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Maria HjorthRosaura Casas
Jan 21, 2011·Physiological Reviews·Tom L van BelleMatthias G von Herrath
Jun 22, 2011·The Journal of Experimental Medicine·Carolin DanielHarald von Boehmer
Mar 16, 2013·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Ken T CoppietersMatthias G von Herrath

❮ Previous
Next ❯

Citations

Aug 2, 2016·Journal of Diabetes Research·Joshua Juwono, Ryan D Martinus
May 5, 2017·International Journal of Molecular Sciences·Tiago Góss SantosGlaucia Noeli Maroso Hajj
Feb 16, 2021·Frontiers in Immunology·Abu Saleh Md MoinAlexandra E Butler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.